RYAH Group

Raising $1M for a global mass marketing launch of the RYAH Wellness line via e-commerce campaigns in key markets

Facebook Twitter LinkedIn

 
RYAH Group Funding Request Document 


RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches, and pens.


RYAH’s Smart Inhaler: 

Used in conjunction with RYAH's mobile App, the inhaler is arguably the best dry herb vaporizer on the market. Its convection heater evenly vaporizes the contents, unlike most vaporizers which tend to burn some of the herb, creating undesirable lung irritants. The patented mouthpiece is designed to ensure a pleasant draw at any temperature the user selects. Finally, through its unique IoT connection, the device controls and reports each inhalation and estimated amounts of THC and CBD consumed, helping the patient follow their prescription. RYAH MD, a web-based App, enables prescribing doctors to track patient usage and therapeutic outcomes.

Clinical Trials

United Kingdom Clinical Trial:
RYAH is supplying all inhalers along with a customized App, supporting the UK's first regulatory-approved clinical trial, "CANPAIN", of the efficacy of cannabis for treating about 5,000 patients suffering from pain. Celadon Pharmaceuticals plans to distribute RYAH products to the National Health Service (NHS) following the clinical trial, conducted by Celadon's subsidiary, LVL Health. During the trial, RYAH expects to supply 5,000 inhalers and 500,000 cartridges, and substantially more when generally available through the NHS.

United States Veterans Trial:
Royal Emerald Pharmaceuticals, of California, has signed a revenue-sharing MoU with RYAH, to use the Smart Inhaler to administer Federally grown medical marijuana to US Veterans nationwide, for treatment of post-traumatic stress disorder (PTSD).

United States COVID Trial:
Omni Medical Services, of Michigan, is also planning multi-state clinical trials, involving up to 11,000 participants, pending FDA approval of the RYAH Smart Inhaler for dose delivery, to study the potential anti-inflammatory effects of cannabis for the prevention and treatment of COVID-19.
If the foregoing US studies proceed as planned, RYAH should supply in excess of 10,000 inhalers and 1,000,000 cartridges. Longer term, the US market potential is enormous.
 
 
European Union Trials
Various clinical trials are planned by RYAH partners in the EU, upon achieving Medical Device Regulation (EU MDR) certification of the Smart Inhaler, expected this year. It is too early to discuss details, but over time, RYAH expects to supply tens of thousands of inhalers and millions of cartridges for trials, and then considerably more as individual EU countries decide to embrace medical cannabis within their national healthcare systems.

Additional Markets:
Based on pending approval as a medical device in Australia, Cannatrek is planning to distribute the RYAH Smart Inhaler there.
RYAH's authorized representative in New Zealand, Medical Kiwi has achieved medical device registration and plans to distribute the RYAH Smart Inhaler.
In Israel, Bazelet is chaperoning the Smart Inhaler through medical device certification and plans to distribute it. Although a small country, Israel is one of the largest national markets for medical cannabis based on per capita usage.
Based on the above, RYAH expects to supply thousands of additional inhalers and hundreds of thousands of cartridges to Australia, New Zealand, and Israel within the coming year.

Milan, Italy Research:
The THC Lab, at the University of Milan, conducted an investigation of the operational efficiency of the RYAH Smart Inhaler. Based on the success of the first study, the University of Milan is currently doing further tests of the RYAH Smart Inhaler employing an artificial lung.

Global Wellness Market:
RYAH's new CEO, Dr. Dave Richards, has said "While absolutely pleased with our progress achieving medical device certifications, approvals and clinical trials leading to opening up various national health systems, we are also going to address the global mass market for wellness. Although the medical market is huge, with millions of patients who will want RYAH Smart Inhalers provided by their health services or insurance, the market for wellness and recreational use of marijuana is even bigger. I consider recreational use an aspect of the wellness market, given that people use cannabis if it makes them feel good. Feeling good is wellness."
Toward the goal of addressing a global mass market, RYAH is actively developing a refillable cartridge solution for the Smart Inhaler 1.0, as well as developing the next generation, Smart Inhaler 2.0, with enhanced features and functionality for both medical devices, and non-medical-device versions for wellness use.
Distribution deals have been established or are in discussion with various dispensaries including Holistic and Curaleaf in the US; Northern Green and Black Rose Organics in Canada; Cannaray and Hilltop Leaf in the UK; Greenstein, 420 Pharma, and Therismos in Germany; Transvaal Apotheek and Cannabis Zorg in the Netherlands; and Pure Holdings in Switzerland. Further, RYAH is looking at various e-commerce options for distributing products globally.


Sales Forecast:
Dr. Dave Richards said "It is too early to offer a forecast of the potential sales to the wellness mass market. However, based on supplying clinical trials alone, RYAH should enjoy revenues in excess of $8 million over the next year or so, from sales of Smart Inhalers and accessories."


Market Pain Points

Regulation: 
  • Lack of admissible data
  • Limited solutions providing dose control
Innovation 
  • Not enough functioning data platforms
  • Machine learning is underused
Big Pharma 
  • Unreliable session review
  • Lack of consistent research
  • Limited ways to integrate existing data
Market Knowledge  
  • Lack of uniformity
  • Poor patient feedback
  • Existing data is unstructured 


Solution

RYAH’s product suite fuses together medicine and data technology using machine learning and AI to provide users with plant-based treatments tailored to their needs and experiences. We’ve created the first-ever IoT solution that captures seed-to-consumption data.


Addressable Target Markets

RYAH incorporates big data into plant-based treatment, creating a unique point where several growing markets are connected. 

Hardware & Software: 
  • Big Data: $229.4B USD by 2025
  • IoT: $1.6T USD by 2025

Health & Wellness:
  • Plant-based Treatment: $27B USD by 2026
  • Nutraceuticals: $226B USD by 2026


IP: The First Cannabis Patent in the AI Industry

AI Ontology: Utility
Patent Number10296714: Issued
Filed May 2016

RYAH Smart Inhaler: Utility
Patent Number15/924172: Pending
Filed March 2018

RYAH Mouthpiece: Design
Patent Number 62/809266: Pending
Filed April 2019

RYAH Filling Line: Design
Application Pending June 2019

RYAH Cartridge: Design
Patent Number62/809266: Pending Filed April 2019

RYAH Patch and Pen: Design 
Applications Filed July 2019

Team 

Dr. Dave Richards - Chief Executive Officer
Francois Desrosiers - Chief Financial Officer
Jordan Medley - VP of Global Product
Sophie Kleshchuk - AVP oo Global Operations
Jules Gagnon - AVP of Investor Relations

 

Ready to Ask For Funding for your company?

Post a Funding Request

RYAH Group is no longer seeking funding.